Is Bio-Rad Laboratories, Inc. (BIO) Overvalued?
We dive into why Bio-Rad Laboratories, Inc. (BIO) could be considered overvalued on 2026-07-24, based on AAII’s Value Score and Grade.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Michael Rose
Michael Rose
Jenna Brashear
Michael Rose
| Share Statistics | BIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8,655.8 | $1,774.7 | 75% |
|
| Shares Out (Mil) | 27.0 | 94.8 | 35% |
|
| Institutional Ownership | 46.0% | 90.1% | 20% |
|
| Float (Mil) | 20.9 | 69.9 | 30% |
|
| Beta | 1.08 | 1.20 | 65% |
|
| Avg Daily Volume (000s) | 353 | 838 | 53% |
|
| Price Change (52-week) |
29.3% | 81.0% | 69% |
|
| Growth | BIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 0.3% | 7.8% | 18% |
|
| Net Income (5yr) | (27.6%) | (13.7%) | 15% |
|
| EPS (5yr) | (26.1%) | 0.7% | 10 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 59.5% | (15.0%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 5 | 5 | |
| Current EPS | $1.745 | $9.002 | $9.722 | |
| Month Ago EPS | $1.745 | $9.002 | $9.722 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 2 | 1 | |
| Three Months Ago EPS | $2.449 | $10.260 | $11.348 | |
| Year/Year Chg | (108.9%) | (67.7%) | (64.8%) | |
| Financials | BIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,590 | $763 | 64% |
|
| Net Income (TTM) (Mil) | $169 | ($14) | 66% |
|
| EPS (TTM) | $6.244 | ($0.200) | 90% |
|
| Operating Cash Flow (TTM) (Mil) | $510 | $53 | 72% |
|
| Net Cash Flow (TTM) (Mil) | ($14) | ($5) | 29% |
|
| Long-Term Debt (Q1) (Mil) | $942 | $270 | 66% |
|
| Enterprise Value (Q1) (Mil) | $8,481 | $2,430 | 71% |
|
| Valuation | BIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.28 | 3.00 | 32% |
|
| P/E | 52.4 | 43.5 | 85% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | BIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 52.0% | 47.6% | 64% |
|
| Net Margin | 6.5% | (2.9%) | 53% |
|
| ROA | 1.7% | (3.2%) | 54% |
|
| ROE | 2.5% | (4.5%) | 39% |
|
| Liabilities to Assets | 30.0% | 43.0% | 21% |
|
| F-Score | 7 | 5 | 84% |
|
Bio-Rad Laboratories, Inc. did not pass any screens on 7/30/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors